Amit Etkin, Alto Neuroscience CEO
January 29, 2024 09:28 AM EST
Financing
Startups

Mid-stage CNS biotech Al­to Neu­ro­science plots $89M IPO

Kyle LaHucik

Senior Reporter

Al­to Neu­ro­science joined Fractyl Health in out­lin­ing its IPO price range on Mon­day morn­ing as the two biotechs look to build on the mo­men­tum gen­er­at­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Evotec gains on Halozyme's takeover pro­pos­al

Adap­ti­m­mune to 're­de­fine' it­self as a sar­co­ma biotech, cuts a third of staffers

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

Eli Lil­ly sues the US gov­ern­ment over its pro­posed 340B re­bate mod­el

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times